Biodel (NASDAQ:ALBO) Research Coverage Started at Roth Capital

Stock analysts at Roth Capital initiated coverage on shares of Biodel (NASDAQ:ALBO) in a research report issued to clients and investors on Wednesday, November 15th, Marketbeat reports. The firm set a “buy” rating and a $92.00 price target on the biopharmaceutical company’s stock. Roth Capital’s price objective points to a potential upside of 277.20% from the company’s current price.

A number of other research analysts also recently weighed in on the company. Zacks Investment Research cut Biodel from a “buy” rating to a “hold” rating in a research report on Monday, November 13th. Needham & Company LLC reiterated a “buy” rating on shares of Biodel in a research note on Thursday, October 26th. ValuEngine lowered Biodel from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Wedbush reiterated an “outperform” rating and issued a $58.00 price objective on shares of Biodel in a research note on Monday, September 11th. Finally, Cowen initiated coverage on Biodel in a research note on Wednesday, August 16th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $53.75.

Biodel (NASDAQ ALBO) opened at $24.39 on Wednesday. Biodel has a 1-year low of $15.31 and a 1-year high of $29.20.

A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC grew its stake in Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 149,632 shares of the biopharmaceutical company’s stock after purchasing an additional 794 shares during the quarter. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent reporting period. Institutional investors own 29.22% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Biodel (NASDAQ:ALBO) Research Coverage Started at Roth Capital” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://weekherald.com/2017/12/04/biodel-inc-albo-earns-buy-rating-from-analysts-at-roth-capital.html.

Biodel Company Profile

Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.

Analyst Recommendations for Biodel (NASDAQ:ALBO)

Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply